eTheRNA is developing mRNA-based products mimicking the action of oncolytic viruses. A mRNA-based approach has several advantages over oncolytic viruses:
A single construct or a mix of naked or packaged mRNA is delivered directly into the tumor site giving direct access to the effector site of the therapy. This modality offers opportunities to develop products with cell-lytic, tumor microenvironment modifying and immune stimulating properties.
Preliminary in vitro and ex vivo experiments have provided impressive anti-tumor responses in both the treated and untreated tumors suggesting a systemic response from a loco-regional delivery.
© 2020 Etherna | Studio Hanswijk